EPERZAN DIN 02443635
Status: Cancelled Pre Market
Holder: GLAXOSMITHKLINE INC
Health Canada record
| Active ingredient(s) | ALBIGLUTIDE 30 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | A10BJ04 ALBIGLUTIDE |
|---|
| Original market date | |
|---|
| Current status date | 24-Oct-2017 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ALBIGLUTIDE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02443643 | EPERZAN | GLAXOSMITHKLINE INC | Powder For Solution | ALBIGLUTIDE 50 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 17080 | 2015-07-15 | New Drug Submission (NDS) | |
Request a quote for EPERZAN
How to read a Canadian DIN record